Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASSION-22: Cadonilimab Adjuvant HCC
NCT05489289Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Jan 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05489289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489289.